Effect of Ritonavir-boosting on Atazanavir Discontinuation due to Jaundice in HIV-infected Koreans.
- Author:
Pyoeng Gyun CHOE
1
;
Wan Beom PARK
;
Kyoung Ho SONG
;
Ji Hwan BANG
;
Eu Suk KIM
;
Sang Won PARK
;
Hong Bin KIM
;
Nam Joong KIM
;
Myoung Don OH
;
Kang Won CHOE
Author Information
- Publication Type:Original Article
- Keywords: HIV; Atazanavir; Ritonavir; Hyperbilirubinemia; Jaundice
- MeSH: Atazanavir Sulfate; Bilirubin; HIV; Humans; Hyperbilirubinemia; Incidence; Jaundice; Liver Diseases; Oligopeptides; Pyridines; Ritonavir
- From:Infection and Chemotherapy 2012;44(3):175-179
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Data regarding differences of intolerance between a ritonavir-unboosted and a ritonavir-boosted atazanavir regimen in HIV-infected Koreans is limited. MATERIALS AND METHODS: A review was conducted of the incidence of severe hyperbilirubinemia (serum total bilirubin >3.1 mg/dL) and discontinuation of atazanavir in HIV-infected patients who had received an atazanavir-containing regimen at Seoul National University Hospital from 2005 to 2009. Patients with active liver disease were excluded from the study. RESULTS: Of a total of 335 patients receiving an atazanavir-containing regimen, 145 (43.3%) received treatment with a ritonavir-boosted regimen. The cumulative incidence of severe hyperbilirubinemia at three months was 40.5% in patients receiving a ritonavir-boosted atazanavir regimen and 21.4% in patients receiving an un-boosted atazanavir regimen (P<0.001). The cumulative incidence of severe hyperbilirubinemia at 12 months was 58.5% in patients receiving a ritonavir-boosted regimen and 41.3% in those receiving an un-boosted regimen (P=0.008). The proportion of drug discontinuation due to jaundice during the 12-month period was 11.7% in patients receiving a ritonavir-boosted regimen and 5.3% in those receiving an un-boosted regimen (P=0.035). CONCLUSIONS: Occurrence of severe hyperbilirubinemia and discontinuation of atazanavir due to jaundice was significantly more common in HIV-infected Koreans who received a ritonavir-boosted atazanavir regimen than in those who received a ritonavir-un-boosted atazanavir regimen.
